HCA Healthcare, Inc.

HCA Healthcare, Inc. (HCA) Market Cap

HCA Healthcare, Inc. has a market capitalization of .

No quote data available.

CEO: Samuel N. Hazen

Sector: Healthcare

Industry: Medical - Care Facilities

IPO Date: 2011-03-10

Website: https://www.hcahealthcare.com

HCA Healthcare, Inc. (HCA) - Company Information

Market Cap: -|Sector: Healthcare

Company Profile

HCA Healthcare, Inc., operating through its subsidiaries, delivers a comprehensive array of healthcare services throughout the United States. The organization manages a network of general and acute care hospitals that provide a full spectrum of medical and surgical care, encompassing inpatient services, intensive care, cardiac treatment, diagnostic procedures, and emergency services. These hospitals additionally offer a broad range of outpatient care, such as ambulatory surgery, laboratory testing, radiology, respiratory therapy, cardiology, and physical therapy. Beyond its hospital infrastructure, HCA Healthcare operates numerous specialized outpatient facilities. These include standalone ambulatory surgery centers, dedicated emergency care facilities, urgent care clinics, walk-in clinics, advanced diagnostic and imaging centers, rehabilitation and physical therapy centers, radiation and oncology treatment facilities, physician practices, and various other healthcare sites. Furthermore, the company oversees psychiatric hospitals, which offer diverse therapeutic programs. These services cater to child, adolescent, and adult psychiatric care, alongside adolescent and adult alcohol and drug abuse treatment and counseling. As of December 31, 2021, HCA Healthcare's extensive portfolio included 182 hospitals, specifically 175 general and acute care hospitals, five psychiatric hospitals, and two rehabilitation hospitals. Its network also featured 125 freestanding surgery centers and 21 freestanding endoscopy centers, all distributed across 20 states and England. Founded in 1968 and formerly known as HCA Holdings, Inc., the company's corporate headquarters are situated in Nashville, Tennessee.

Analyst Sentiment

69%
Buy

From 26 Active Polls

1Y Forecast: $460.18

▲ +0.0% Potential Upside

Consensus Target Metrics

Low Bound

$369

Median

$450

High Bound

$579

Average

$460

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$460.18
▲ +14.30% Upside
Low Target
$369.00
-8% Risk
Median Target
$450.00
12% Mid
High Target
$579.00
44% Max

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

Sentiment volume allocation data unavailable.

Historical valuation matrix unavailable.

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 HCA HEALTHCARE INC (HCA) — Investment Overview

🧩 Business Model Overview

HCA operates a portfolio of acute-care hospitals and affiliated outpatient facilities. Revenue is generated when patients receive inpatient and outpatient clinical services, with reimbursement driven primarily by payer mix (commercial insurers, Medicare, and Medicaid) and negotiated payment rates. The company also benefits from provider network integration through employed physicians, hospital-based specialty services, and referral patterns that support care continuity across settings (emergency, inpatient, and outpatient).

Operationally, HCA’s “value chain” is: (1) secure and maintain clinical capacity and service lines in defined service areas, (2) manage patient flow through emergency and referral sources, (3) deliver care with cost discipline (labor, supplies, and facility utilization), and (4) contract with payers to align reimbursement with care delivery. Patient demand is relatively recurring; demand variability is mitigated by broad service coverage and physician/community referral relationships.

💰 Revenue Streams & Monetisation Model

Monetisation is largely transactional but exhibits stability due to the recurring nature of acute care. Revenue drivers include:

  • Inpatient services: Surgical and medical admissions, with revenue influenced by case mix and acuity.
  • Outpatient services: Emergency department visits and a growing set of outpatient procedures and specialty services.
  • Ancillary services: Imaging, labs, pharmacy, and other hospital-based services that often attach to broader episodes of care.
  • Payer reimbursement structure: Reimbursement is driven by negotiated commercial rates, Medicare payment rules, and Medicaid program specifics (which vary by state).

Primary margin drivers typically include: (1) labor productivity and staffing model effectiveness, (2) occupancy/utilization and throughput, (3) supply chain and procurement leverage, (4) payor contracting outcomes and mix of insured patients, and (5) the mix of higher-acuity inpatient services and profitable outpatient growth relative to cost structure.

🧠 Competitive Advantages & Market Positioning

HCA’s moat is best characterized as a combination of scale-driven cost advantages, regulatory and capital barriers, and integrated care delivery that reinforces referral and continuity. While healthcare demand is not “switchable” in the same way software platforms are, patients and referring clinicians still face meaningful practical friction when switching hospitals—especially for specialty services, physician alignment, and established care pathways.

Key moat elements

  • High barriers to entry (regulatory + capital intensity): Building and operating acute-care capacity requires substantial capital, extensive clinical staffing, and regulatory approvals that can be difficult to replicate quickly.
  • Operational scale and purchasing leverage: Large volume supports procurement efficiency and standardized operating practices across facilities.
  • Provider alignment and referral stickiness: Employed physicians and specialty coverage can strengthen referral capture in the service areas HCA serves.
  • Integrated ecosystem across care settings: Emergency-to-inpatient-to-outpatient pathways support revenue capture across episodes and can reduce leakage versus purely single-site operators.

Competitive benchmarking

  • Universal Health Services (UHS): UHS is a major healthcare services operator with a significant focus on behavioral health and acute-care segments. Compared with UHS, HCA’s positioning is more heavily weighted toward large acute-care hospital networks with extensive general and specialty services.
  • Tenet Healthcare (THC): Tenet also operates acute-care hospitals and outpatient facilities in competitive markets. HCA’s scale across a broader footprint can enhance purchasing leverage and operational standardization relative to smaller or more regionally concentrated peers.
  • Community Health Systems (CYH): CYH focuses on community hospitals, often with different market dynamics and operational execution constraints. HCA’s network breadth and associated integration across service lines typically provide greater ability to manage fixed-cost structures and optimize case mix.

🚀 Multi-Year Growth Drivers

Over a 5–10 year horizon, growth is supported by secular healthcare utilization trends and capacity/portfolio development:

  • Demographics and demand for acute services: Aging populations increase utilization of inpatient and outpatient clinical services, including chronic disease management episodes that flow into acute care.
  • Shift toward outpatient and facility-based care: Migration from inpatient settings to outpatient procedures and ambulatory services can support revenue growth if paired with disciplined cost control.
  • Service line depth and specialty care expansion: Expanding specialty programs and higher-acuity service offerings can improve case mix and strengthen referral capture.
  • Capacity augmentation and geographic portfolio optimization: Select facility expansions, new campuses, and upgrades can address local demand while maintaining economies of scale.
  • Value-based and payer contracting evolution: Contracting models that reward quality, outcomes, and utilization management can support longer-run pricing stability if HCA’s operational systems reduce avoidable utilization.

⚠ Risk Factors to Monitor

  • Regulatory reimbursement pressure: Changes to Medicare/Medicaid payment models, wage index rules, or site-of-service reimbursement can compress margins.
  • Payer mix and contracting dynamics: Greater commercial reimbursement pressure or unfavorable contract renewals can affect net revenue per case.
  • Labor costs and staffing constraints: Healthcare delivery is labor-intensive; sustained labor cost inflation or staffing shortages can impair operating margins.
  • High capital intensity and leverage: Continued facility upgrades, technology investments, and interest expense exposure can impact free cash flow and financial flexibility.
  • Utilization and acuity volatility: Patient volumes and case mix can fluctuate with economic conditions and public health events.
  • Legal, compliance, and cybersecurity risks: Hospitals face substantial compliance obligations and increasing cybersecurity exposure that can lead to direct costs and reputational damage.

📊 Valuation & Market View

Hospital operators are typically valued on earnings power and cash generation, with the market often focusing on EV/EBITDA and earnings-based multiples and the quality of operating margins and free cash flow. Key valuation sensitivities include:

  • Operating margin trajectory: Labor productivity, supply chain discipline, and utilization/occupancy are central.
  • Reimbursement outlook: Expected changes in Medicare/Medicaid and commercial contract terms influence sustainable net revenue.
  • Capital allocation and leverage: The pace of capex and debt structure affects financial resilience through reimbursement and labor cycles.
  • Portfolio mix: Service line mix (higher acuity, specialty depth, outpatient contribution) can influence both growth and margin durability.

In general, the market assigns value to operators with credible execution on cost discipline, consistent reimbursement outcomes, and manageable leverage through the reimbursement and labor cycle.

🔍 Investment Takeaway

HCA’s long-term investment case is anchored in durable structural advantages: large-scale cost efficiency, high barriers to entry from capital and regulatory requirements, and an integrated care delivery ecosystem that supports referral and revenue capture across inpatient and outpatient settings. The investment outcome depends on maintaining operating discipline through reimbursement and labor cycles while managing the capital intensity required to sustain clinical capacity and technology investments.


⚠ AI-generated — informational only. Validate using filings before investing.

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-06-30

"HCA reported Q2 2026 revenue of $20.3B and net income of $1.70B, with diluted EPS of $7.62. YoY, revenue grew 8.6% (vs. Q2 2025) and net income declined 10.1% (from $1.89B to $1.70B), implying earnings pressure despite top-line growth. QoQ, revenue rose 5.8% (from $19.1B in Q1 2026) while net income increased 4.9% (from $1.62B). Margins in Q2 softened on an accounting basis: gross profit ratio was 15.2% in Q2 2026 vs. 15.0% in Q1 2026 (slightly up), but far below Q4/Q3 2025 levels where gross margins were ~41%—suggesting mix/classification noise across the dataset. Net profit margin was 8.4% in Q2 2026, down modestly vs Q1 (8.5%). Cash generation remained strong: operating cash flow was $2.34B and free cash flow was $1.10B in the quarter. The company continued capital returns via buybacks ($2.06B) alongside a small dividend ($171M). Balance sheet resilience is constrained by structurally negative total equity in the provided data, while total assets were steady around ~$60.5–$61.5B; leverage remains high with total debt ~$48.8B and interest coverage ~5.1x. On shareholder returns, the stock price rose 47.4% over the last year (strong momentum), and the dividend yield was ~0.2%, so total return was driven primarily by capital appreciation."

Revenue Growth

Good

Revenue increased 8.6% YoY (Q2’26: $20.3B vs Q2’25: $18.6B) and 5.8% QoQ (vs Q1’26: $19.1B).

Profitability

Neutral

Net income declined 10.1% YoY (to $1.70B) despite QoQ growth of 4.9%. Net margin was ~8.4% in Q2’26 vs ~8.5% in Q1’26, indicating mild profit pressure.

Cash Flow Quality

Good

Operating cash flow of $2.34B and free cash flow of $1.10B in Q2’26. Buybacks ($2.06B) and dividends ($171M) were supported by strong FCF.

Leverage & Balance Sheet

Fair

High leverage with total debt ~ $48.8B and interest coverage ~5.1x. Total equity is negative in the dataset, limiting balance-sheet flexibility.

Shareholder Returns

Strong

Strong price momentum: +47.4% over 1 year. Dividend yield is low (~0.2%), but buybacks were substantial, supporting total shareholder value.

Analyst Sentiment & Valuation

Positive

Consensus target ~$458.6 vs current price ~$488 implies modest upside/(near-term downside) versus expectations; valuation metrics appear elevated in provided ratios.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

HCA delivered +11% diluted EPS growth in Q2 and +11% year-to-date despite a meaningful payer-mix shock from expiring enhanced premium tax credits and ongoing exchange disenrollment. Exchanges fell 15% in the quarter; patients reportedly migrated almost 1-for-1 to uninsured, driving most of the earnings pressure. Management increased full-year exchange headwind assumptions to -$1.0B to -$1.2B adjusted EBITDA (from prior thinking), largely because the uninsured conversion and utilization impact did not behave as originally modeled. Offsetting strength came from Medicaid supplemental payment programs, with +$400M incremental net benefit recognized in Q2, including a large Florida program contribution. Operating performance remained supported by cost discipline from the financial resiliency program; same-facility cost per equivalent admission was essentially flat YoY (and +1.4% sequentially). Guidance maintains a wide 2026 range with back-half dynamics tied to exchange timing and Medicaid program net timing. The outlook remains cautious due to elective surgery softness and potential 2027 Medicaid work-requirement risk.

AI IconGrowth Catalysts

  • Emergency room visits increased 3.6% in 2Q26; emergent inpatient cases up ~2% YoY (2025 vs 2024 and through first 6 months of 2026).
  • Insured volumes excluding exchanges grew +3.2% in 2Q26 and +2.2% YTD (improving trends over first half).
  • Medicaid supplemental payment programs partially offset payer mix pressure, generating $400M net incremental EBITDA impact in the quarter (including Florida).
  • Capacity expansion and facility additions supported demand: >$7B approved CapEx to come online over the next 3 years; plan includes ~1,000–1,200 inpatient beds and ~250–300 outpatient facilities in/around late 2026–early 2027.

Business Development

  • Medicaid supplemental payment programs—incremental net benefit recognized tied to a Florida program (approved Oct 1, 2024 to Jun 30, 2026).
  • No explicit named commercial customer/vendor partnerships disclosed in the transcript beyond state-level Medicaid program approvals (e.g., Florida; Texas mentioned for Medicaid conversions).

AI IconFinancial Highlights

  • Diluted EPS growth: +11% in the quarter and +11% YTD.
  • Admissions: +2.5% and equivalent admissions +2.7% in 2Q26 YoY; ER visits +3.6% YoY.
  • Surgeries: inpatient surgeries -2.3% YoY; outpatient surgeries -3.4% YoY.
  • Payer mix: exchanges declined 15%; patients migrating nearly 1-for-1 from exchanges to uninsured; management estimates this explains ~80% of uninsured volume growth (remaining ~20% from decreased Medicaid conversions, mostly Texas).
  • Net revenue per equivalent admission: +6.4% YoY in the quarter, reflecting payment benefits; contracted rate increases and governmental payment updates offset exchange/service mix negativity.
  • Adjusted EBITDA impact from payer mix shift: approximately -$400M in 2Q26, including +$75M as an increase vs prior first-quarter exchange impact estimate.
  • Medicaid supplemental payments: +$400M incremental net benefit recognized in the quarter; includes +$540M from recently approved Florida program (partially offset by $25M of retro payments received in 2Q).
  • Resiliency/costs: same-facility cost per equivalent admission essentially flat YoY (when considering Medicaid supplemental payment programs) and improved +1.4% sequentially.

AI IconCapital Funding

  • 2Q26 CapEx: $1.2B.
  • 2Q26 share repurchases: $2.1B purchased of outstanding shares.
  • 2Q26 dividends: $171M.
  • Operating cash flow: $2.3B, -45% YoY due to cash timing differences for Florida Medicaid supplemental payments and prior-year deferral of federal income tax payments to 4Q25.
  • Debt-to-adjusted EBITDA leverage: in the lower half of stated target range; balance sheet described as strong and positioned for the future.

AI IconStrategy & Ops

  • Financial resiliency program emphasis: digital transformation, global capabilities, and enhanced workforce development to generate efficiencies and bend the cost curve.
  • OR and network investment strategy to address surgical mix: investing in ORs/equipment for inpatient flow and optimizing patient/physician operations.
  • ASC strategy: ASC division showed earnings growth in the first 6 months; more units, slightly higher overall volume YoY, and growing acuity; continuing to add capacity.

AI IconMarket Outlook

  • Updated full-year 2026 guidance (range): Revenue $77.0B–$79.5B; Adjusted EBITDA $15.4B–$16.1B; Net income $6.3B–$6.7B; Diluted EPS $28.70–$30.50.
  • Exchange headwind assumption included in guidance: -$1.0B to -$1.2B adjusted EBITDA impact (full-year).
  • Medicaid supplemental payment programs included in guidance: +$300M to +$500M net benefit (full-year); updated implies -$100M to -$300M headwind in the back half due to program approvals/retro payments received in 2025 exceeding incremental Florida benefit.
  • Quarterly pacing: management expects 4Q adjusted EBITDA growth vs prior year to be higher than 3Q, based on assumed timing effects of exchanges, Medicaid supplemental payment programs, and resiliency.

AI IconRisks & Headwinds

  • Health insurance exchange reforms/coverage loss: management revised exchange-driven adjusted EBITDA impact to -$1.0B to -$1.2B, primarily because uncovered patients are becoming uninsured nearly 1-for-1 (vs original 80–85% uninsured assumption).
  • Utilization decline assumption not materializing: expected lower utilization for newly uninsured patients did not occur as originally assumed.
  • Medicaid supplemental payment timing and net benefit uncertainty: back-half headwind of -$100M to -$300M implied by guidance update.
  • Elective surgery softness: elective inpatient down ~6% YoY in 2026 vs down 2% in 2025; outpatient largely elective; management links part to exchange-related demand and broader affordability pressures.
  • Provider tax inflation: other operating expenses inflated due to provider tax/waiver; professional fees up ~8.5% same-facility YoY (moderated sequentially).
  • Regulatory risk: proposed Medicaid work requirements for 2027—management expects higher impact in expansion states; notes ~40% of Medicaid revenues are expansion-state vs 60% non-expansion.

Q&A: Analyst Interest

  • Exchange headwind mechanics and updated magnitude: Management explained that first-half exchange volume declines held at ~15% in both 1Q and 2Q, matching original guidance, but updated the uninsured conversion to nearly 1-for-1 (vs 80–85%) as the key driver for the larger -$1.0B to -$1.2B estimate.
  • Surgery declines—elective vs emergent, and attribution: Management detailed inpatient surgeries split between ~2/3 emergent (ER-driven) up ~2% YoY and ~1/3 elective down more this year; elective inpatient down ~6% YoY vs -2% last year. They attributed most outpatient weakness to HICS-driven demand declines and mentioned Medicare rule migration shifting cases inpatient-to-outpatient.
  • Back-half EBITDA bridge and cost initiatives: Management emphasized three back-half confidence drivers—volume continuity (insured ex-exchange momentum), cost trajectory improvement from resiliency execution, and operating leverage. They did not provide a line-item surgical/deductible bridge but highlighted visibility into resiliency performance and multiyear digital/global/shared-services benefits.

Sentiment: CAUTIOUS

Note: This summary was synthesized by AI from the HCA Q2 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Loading financial data and tables...
© 2026 Stock Market Info — HCA Healthcare, Inc. (HCA) Financial Profile